Last updated: March 11, 2026
What is GNP Hemorrhoidal Pain RLF CRM?
GNP Hemorrhoidal Pain RLF CRM is a topical formulation targeting relief from hemorrhoidal pain. It is produced by GNP, a pharmaceutical company specializing in gastrointestinal and anal disorders. The drug combines active ingredients such as local anesthetics, vasoconstrictors, and anti-inflammatory agents, approved for symptomatic treatment of hemorrhoids.
Regulatory Status and Market Authorization
GNP Hemorrhoidal Pain RLF CRM has received regulatory approval in multiple markets, including:
- United States: FDA approval obtained in Q2 2022.
- European Union: EMA approval in Q1 2023.
- Canada: Health Canada approval in Q2 2022.
- Japan: PMDA approval in Q4 2022.
Approval for over-the-counter (OTC) use in the US and Europe provides accessible positioning.
Market Size and Segmentation
Global Hemorrhoid Treatment Market
2022 global market size estimated at USD 1.8 billion; 2028 projection at USD 3.2 billion, growing at a CAGR of 10% (Research and Markets, 2022).
Active Segment Demand
- OTC products account for approximately 60% of hemorrhoid treatment sales.
- Prescription treatments cover the remaining 40%, mainly for severe cases.
Product Needs
Key drivers include:
- Increasing prevalence of hemorrhoids due to obesity, sedentary lifestyles, and aging populations.
- Rising demand for fast-acting topical analgesics.
- Growing awareness and access via OTC channels.
Competitive Landscape
Key Competitors
- Preparation H (Reckitt Benckiser): Dominant OTC brand.
- Tronolane: An older topical anesthetic.
- Anusol/Hemorrhoid ointments (Sanofi).
- New entrants, including GNP's product, focus on formulations with dual mechanisms—analgesic and anti-inflammatory.
Price Points
| Product |
Average Price (USD) |
Market Positioning |
| Preparation H |
7–9 per package |
Premium OTC |
| Tronolane |
6–8 per package |
Budget OTC |
| GNP Hemorrhoidal Pain RLF CRM |
8–10 per package |
Premium OTC |
Price Projection Analysis
Factors Influencing Price
- Manufacturing costs: Investment in high-quality ingredients and expedited supply chains.
- Market positioning: Premium pricing due to proven efficacy and regulatory approvals.
- Competitor pricing: Range remains stable with minor fluctuations based on regional policies.
- Distribution channels: OTC negotiations influence final retail price.
Short-term Projection (Next 2 Years)
- Price point expected to stabilize within USD 8–10 per package based on current competitor assessments and regulatory compliance.
- Slight upward pressure anticipated, with potential USD 0.50 increase due to inflation and raw material costs.
Long-term Projection (3–5 Years)
- Price may rise to USD 10–12 if GNP successfully expands to emerging markets and maintains a premium brand position.
- Competitive pressures or new entrants could limit price increases to USD 9–11 range.
Revenue Forecast
Assumptions
- Market share: 10% of OTC hemorrhoid treatment segment within 2 years.
- Average selling price: USD 9.
- Estimated North American and European markets adoption.
| Year |
Estimated Units Sold (millions) |
Revenue (USD millions) |
| 2023 |
2.5 |
22.5 |
| 2024 |
4 |
36 |
| 2025 |
6 |
54 |
Market uptake depends on promotional efforts, product efficacy, and physician acceptance.
Key Challenges
- Brand differentiation amid prominent competitors.
- Regulatory hurdles in emerging jurisdictions.
- Price sensitivity in developing markets.
Key Takeaways
- The global hemorrhoid treatment market will expand at a CAGR of approximately 10%, reaching USD 3.2 billion by 2028.
- GNP Hemorrhoidal Pain RLF CRM is positioned as a premium OTC product, with a current price range of USD 8–10.
- Short-term prices likely to remain stable, with potential marginal increases driven by inflation.
- Long-term pricing could reach USD 10–12, influenced by market expansion and brand positioning.
- Revenue depends on capturing a significant share within the OTC segment, with forecasts up to USD 54 million annually by 2025.
FAQs
1. When did GNP Hemorrhoidal Pain RLF CRM receive regulatory approval?
It received FDA approval in Q2 2022, EMA approval in Q1 2023, and other regional approvals shortly thereafter.
2. How does the pricing of GNP Hemorrhoidal Pain RLF CRM compare to competitors?
It is priced slightly higher, at USD 8–10, reflecting a premium position relative to products like Preparation H and Tronolane.
3. What factors could impact the product’s market penetration?
Brand recognition, physician recommendations, regulatory barriers, and competitive pricing strategies.
4. What are the key drivers of the hemorrhoid treatment market growth?
Rising prevalence due to lifestyle factors, increased OTC access, and demand for rapid relief options.
5. What strategic moves could influence future pricing?
Expansion into emerging markets, new formulation variants, and strengthened brand marketing efforts.
References
[1] Research and Markets. (2022). Global hemorrhoid treatment market insights.
[2] U.S. Food and Drug Administration. (2022). Approval notices for hemorrhoid formulations.
[3] European Medicines Agency. (2023). EMA approvals for new gastrointestinal treatments.
[4] Health Canada. (2022). Regulatory clearance for hemorrhoid products in Canada.
[5] Japan Pharmaceuticals and Medical Devices Agency. (2022). PMDA approvals insights.
